Difference between revisions of "Types/bladder/research"
(Marked this version for translation) |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | == Bladder Cancer Research == | + | <languages/> |
| + | <translate> | ||
| + | == Bladder Cancer Research == <!--T:1--> | ||
| + | <!--T:2--> | ||
'''Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer''' | '''Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer''' | ||
| + | <!--T:3--> | ||
Posted: August 9, 2019 | Posted: August 9, 2019 | ||
| + | <!--T:4--> | ||
New clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes. | New clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes. | ||
| + | <!--T:5--> | ||
'''FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer''' | '''FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer''' | ||
| + | <!--T:6--> | ||
Posted: July 26, 2018 | Posted: July 26, 2018 | ||
| + | <!--T:7--> | ||
FDA has changed the approved uses of the immunotherapy drugs pembrolizumab (Keytruda) and atezolizumab (Tecentriq) to treat the most common form of bladder cancer. The change is based on whether patients’ tumors have a specific biomarker. | FDA has changed the approved uses of the immunotherapy drugs pembrolizumab (Keytruda) and atezolizumab (Tecentriq) to treat the most common form of bladder cancer. The change is based on whether patients’ tumors have a specific biomarker. | ||
| + | <!--T:8--> | ||
'''New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers''' | '''New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers''' | ||
| + | <!--T:9--> | ||
Posted: May 31, 2018 | Posted: May 31, 2018 | ||
| + | <!--T:10--> | ||
Flushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of low-grade bladder cancer returning, according to the results of a large clinical trial. | Flushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of low-grade bladder cancer returning, according to the results of a large clinical trial. | ||
| + | <!--T:11--> | ||
'''FDA Approves Immunotherapy Drugs for Patients with Bladder Cancer''' | '''FDA Approves Immunotherapy Drugs for Patients with Bladder Cancer''' | ||
| + | <!--T:12--> | ||
Posted: May 30, 2017 | Posted: May 30, 2017 | ||
| + | <!--T:13--> | ||
The FDA has approved four immunotherapy drugs—avelumab, atezolizumab, durvalumab, and pembrolizumab—for the treatment of patients with bladder cancer. All four drugs belong to a class of cancer therapies known as checkpoint inhibitors. | The FDA has approved four immunotherapy drugs—avelumab, atezolizumab, durvalumab, and pembrolizumab—for the treatment of patients with bladder cancer. All four drugs belong to a class of cancer therapies known as checkpoint inhibitors. | ||
| + | <!--T:14--> | ||
'''FDA Approves Nivolumab for Bladder Cancer''' | '''FDA Approves Nivolumab for Bladder Cancer''' | ||
| + | <!--T:15--> | ||
Posted: March 1, 2017 | Posted: March 1, 2017 | ||
| + | <!--T:16--> | ||
The FDA has approved nivolumab for the treatment of unresectable locally advanced or metastatic bladder cancer that worsened after treatment with platinum-based chemotherapy. | The FDA has approved nivolumab for the treatment of unresectable locally advanced or metastatic bladder cancer that worsened after treatment with platinum-based chemotherapy. | ||
| + | <!--T:17--> | ||
'''FDA Approves New Immunotherapy Drug for Bladder Cancer''' | '''FDA Approves New Immunotherapy Drug for Bladder Cancer''' | ||
| + | <!--T:18--> | ||
Posted: June 7, 2016 | Posted: June 7, 2016 | ||
| + | <!--T:19--> | ||
The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer. | The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer. | ||
| + | <!--T:20--> | ||
'''Elevated bladder cancer risk in New England and arsenic in drinking water from private wells''' | '''Elevated bladder cancer risk in New England and arsenic in drinking water from private wells''' | ||
| + | <!--T:21--> | ||
Posted: May 2, 2016 | Posted: May 2, 2016 | ||
| + | <!--T:22--> | ||
A new study has found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont for over 50 years. | A new study has found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont for over 50 years. | ||
| + | <!--T:23--> | ||
'''TCGA bladder cancer study reveals potential drug targets, similarities to several cancers''' | '''TCGA bladder cancer study reveals potential drug targets, similarities to several cancers''' | ||
| + | <!--T:24--> | ||
Posted: January 29, 2014 | Posted: January 29, 2014 | ||
| + | <!--T:25--> | ||
Investigators with TCGA have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease. They also discovered that, at the molecular level, some subtypes of bladder cancer resemble subtypes of breast, head and neck and lung cancers, suggesting similar routes of development. | Investigators with TCGA have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease. They also discovered that, at the molecular level, some subtypes of bladder cancer resemble subtypes of breast, head and neck and lung cancers, suggesting similar routes of development. | ||
| + | <!--T:26--> | ||
'''Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical Surgery''' | '''Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical Surgery''' | ||
| + | <!--T:27--> | ||
Posted: May 14, 2012 | Posted: May 14, 2012 | ||
| + | <!--T:28--> | ||
Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects. | Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects. | ||
| + | </translate> | ||
Latest revision as of 21:56, 29 October 2019
Bladder Cancer Research
Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer
Posted: August 9, 2019
New clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes.
FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer
Posted: July 26, 2018
FDA has changed the approved uses of the immunotherapy drugs pembrolizumab (Keytruda) and atezolizumab (Tecentriq) to treat the most common form of bladder cancer. The change is based on whether patients’ tumors have a specific biomarker.
New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers
Posted: May 31, 2018
Flushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of low-grade bladder cancer returning, according to the results of a large clinical trial.
FDA Approves Immunotherapy Drugs for Patients with Bladder Cancer
Posted: May 30, 2017
The FDA has approved four immunotherapy drugs—avelumab, atezolizumab, durvalumab, and pembrolizumab—for the treatment of patients with bladder cancer. All four drugs belong to a class of cancer therapies known as checkpoint inhibitors.
FDA Approves Nivolumab for Bladder Cancer
Posted: March 1, 2017
The FDA has approved nivolumab for the treatment of unresectable locally advanced or metastatic bladder cancer that worsened after treatment with platinum-based chemotherapy.
FDA Approves New Immunotherapy Drug for Bladder Cancer
Posted: June 7, 2016
The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer.
Elevated bladder cancer risk in New England and arsenic in drinking water from private wells
Posted: May 2, 2016
A new study has found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont for over 50 years.
TCGA bladder cancer study reveals potential drug targets, similarities to several cancers
Posted: January 29, 2014
Investigators with TCGA have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease. They also discovered that, at the molecular level, some subtypes of bladder cancer resemble subtypes of breast, head and neck and lung cancers, suggesting similar routes of development.
Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical Surgery
Posted: May 14, 2012
Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects.
